Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)
Status:
Not yet recruiting
Trial end date:
2023-06-16
Target enrollment:
Participant gender:
Summary
PL8177 will be given orally once daily to adult ulcerative colitis patients. Patients meeting
eligibility criteria will be randomized to receive either PL8177 or placebo (3:1) for a
treatment period of 8 weeks followed by a 4-week post-treatment period.